We are live on ! Find out more
VVOS icon

Vivos Therapeutics
VVOS

37 hedge funds and large institutions have $9.14M invested in Vivos Therapeutics in 2021 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 11 increasing their positions, 3 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 3

89% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 9

28% more funds holding

Funds holding: 29 → 37 (+8)

24% more call options, than puts

Call options by funds: $707K | Put options by funds: $568K

0.01% less ownership

Funds ownership: 0.41% → 0.4% (-0.01%)

16% less capital invested

Capital invested by funds: $10.9M → $9.14M (-$1.8M)

Holders
37
Holders Change
+8
Holders Change %
+27.59%
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
11
Reduced
3
Closed
9
Calls
$707K
Puts
$568K
Net Calls
+$139K
Net Calls Change
+$139K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$981K
2
Two Sigma Investments
Two Sigma Investments
New York
+$661K
3
AIA
Avalon Investment & Advisory
Texas
+$587K
4
Citadel Advisors
Citadel Advisors
Florida
+$333K
5
Credit Agricole
Credit Agricole
France
+$248K

Top Sellers

Rank Fund Capital Flow
1
RA
Royce & Associates
New York
-$1.72M
2
PCM
Penn Capital Management
Pennsylvania
-$1.11M
3
ACM
Archon Capital Management
Washington
-$1.06M
4
MAG
Millrace Asset Group
Pennsylvania
-$465K
5
KPF
K2 Principal Fund
Ontario, Canada
-$320K
Name Holding Trade Value Shares
Change 		Change in
Stake
FMP
26
Financial Management Professionals
Texas
$24K +$10.7K +102 +76%
Rockefeller Capital Management
27
Rockefeller Capital Management
New York
$14K – – –
UBS Group
28
UBS Group
Switzerland
$12K +$2.31K +22 +23%
Morgan Stanley
29
Morgan Stanley
New York
$10K +$4.41K +42 +71%
Wells Fargo
30
Wells Fargo
California
$8K +$8.62K +82 +4,100%
KA
31
Kozak & Associates
Colorado
$5K +$5.04K +48 New
Royal Bank of Canada
32
Royal Bank of Canada
Ontario, Canada
$3K +$2.84K +27 New
GRP
33
Global Retirement Partners
California
$2K – – –
CG
34
Cutler Group
California
$2K +$2.1K +20 New
TFA
35
Toth Financial Advisory
Virginia
$1K – – –
WWMSC
36
Wagner Wealth Management (South Carolina)
South Carolina
$1K – – –
QT
37
Quantbot Technologies
New York
$1K +$2K +19 New
RA
38
Royce & Associates
New York
– -$1.72M -13,920 Closed
PCM
39
Penn Capital Management
Pennsylvania
– -$1.11M -8,936 Closed
ACM
40
Archon Capital Management
Washington
– -$1.06M -8,600 Closed
Walleye Capital
41
Walleye Capital
New York
– -$743 -6,000 Closed
MAG
42
Millrace Asset Group
Pennsylvania
– -$465K -3,760 Closed
KPF
43
K2 Principal Fund
Ontario, Canada
– -$320K -2,590 Closed
Renaissance Technologies
44
Renaissance Technologies
New York
– -$95K -768 Closed
Millennium Management
45
Millennium Management
New York
– -$65K -527 Closed
IWM
46
IHT Wealth Management
Illinois
– -$61K -493 Closed
1
2

VVOS Hedge Fund Activity: Q3 2021 in Review

37 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q3 2021, worth a combined $9.14M — down 16% from $10.9M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new VVOS positions and 9 closed out — a net gain of 8 holders — while 11 added to existing stakes and 3 trimmed.

The largest buyer was Vanguard Group, adding an estimated $981K. The largest seller was Royce & Associates, exiting entirely with an estimated $1.72M sold.

  • 37 institutional investors held Vivos Therapeutics (VVOS) as of Q3 2021, up from 29 in Q2 2021.
  • Funds reported $9.14M of Vivos Therapeutics stock for Q3 2021, down 16% quarter-over-quarter.
  • 17 funds opened new Vivos Therapeutics positions in Q3 2021 and 9 closed out, a net change of +8 holders.
  • The largest Vivos Therapeutics buyer in Q3 2021 was Vanguard Group, an estimated $981K added.
  • The largest Vivos Therapeutics seller in Q3 2021 was Royce & Associates, an estimated $1.72M sold.

Based on aggregated 13F filings for Q3 2021.